Johnson & Johnson (JNJ)

JNJ on New York Consolidated

94.33USD
31 Aug 2015
Change (% chg)

$-0.84 (-0.88%)
Prev Close
$95.17
Open
$94.88
Day's High
$95.17
Day's Low
$94.27
Volume
3,487,178
Avg. Vol
7,940,907
52-wk High
$109.49
52-wk Low
$81.79

JNJ

Chart for JNJ

About

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and... (more)

Overall

Beta: 0.64
Market Cap(Mil.): $263,535.81
Shares Outstanding(Mil.): 2,769.11
Dividend: 0.75
Yield (%): 3.15

Financials

  JNJ Industry Sector
P/E (TTM): 16.76 35.90 36.13
EPS (TTM): 5.68 -- --
ROI: 14.75 15.37 14.83
ROE: 21.59 15.94 15.69
Search Stocks

J&J sells popular Splenda sugar substitute to Heartland Food

- Johnson & Johnson on Tuesday said it was selling its widely used Splenda sugar substitute to privately held Heartland Food Products Group in order to focus on other consumer brands.

25 Aug 2015

UPDATE 2-J&J sells popular Splenda sugar substitute to Heartland Food

Aug 25 - Johnson & Johnson on Tuesday said it was selling its widely used Splenda sugar substitute to privately held Heartland Food Products Group in order to focus on other consumer brands.

25 Aug 2015

Cherokee Nation sues J&J for Risperdal refund

- Nearly two years after Johnson & Johnson and its Janssen Pharmaceutical unit reached a $2.2 billion settlement with the U.S. Justice Department over the marketing of the antipsychotic drug Risperdal, the drug companies are facing a similar suit by the Cherokee Nation.

28 Jul 2015

Interpublic reports better-than-expected revenue

- Advertising company Interpublic Group of Cos Inc's revenue trumped expectations for the seventh straight quarter as higher advertising spending by U.S. businesses made up for the strong dollar's impact on international revenue.

22 Jul 2015

Johnson & Johnson second-quarter sales wilt on strong dollar, weak device sales

- Johnson & Johnson on Tuesday reported sharply lower sales in the second quarter, and cited a stronger U.S. dollar, disappointing sales of its medical devices and plunging demand for a hepatitis C drug faced with strong competition.

14 Jul 2015

UPDATE 2-J&J 2nd-qtr sales wilt on strong dollar, weak device sales

July 14 - Johnson & Johnson on Tuesday reported sharply lower sales in the second quarter, and cited a stronger U.S. dollar, disappointing sales of its medical devices and plunging demand for a hepatitis C drug faced with strong competition.

14 Jul 2015

BRIEF-J&J CFO sees little impact from Greece debt resolution

* J&J CFO says does not expect Greece debt resolution to affect company sales, earnings unless there is significant change from expected resolution

14 Jul 2015

J&J profit rises 4 pct on pharma sales

July 14 - Johnson & Johnson reported a 4 percent rise in quarterly profit as sales of its mainstay older drugs managed to offset the impact of a strong dollar on overseas revenue.

14 Jul 2015

MDL sought for Johnson & Johnson power morcellator lawsuits

- Lawyers for six women suing Johnson & Johnson over injuries allegedly caused by its power morcellator medical devices have sought to consolidate more than 20 similar lawsuits in Kansas federal court.

22 Jun 2015

U.S. current account widens on weak exports, overseas profits

WASHINGTON - The U.S. current account deficit widened in the first quarter to its highest level since 2012 likely due to the strong dollar's drag on overseas profits and exports.

18 Jun 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : Wright Reports
$75.00
Provider : New Constructs, LLC
$25.00
Provider : Wright Reports
$169.00
Provider : Wright Reports
$169.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks